deferoxamine has been researched along with cytochalasin d in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Aust, AE; Baldys, A | 1 |
| Bortner, BA; Dahners, LE; Draeger, RW; Leatherwood, WH; Rubin, J; Weinhold, PS | 1 |
2 other study(ies) available for deferoxamine and cytochalasin d
| Article | Year |
|---|---|
Role of iron in inactivation of epidermal growth factor receptor after asbestos treatment of human lung and pleural target cells.
Topics: Asbestos; Asbestos, Crocidolite; Carcinogens; Cell Line; Cytochalasin B; Cytochalasin D; Deferoxamine; Dose-Response Relationship, Drug; Endocytosis; ErbB Receptors; Humans; Iron; Iron Chelating Agents; Lung; Mineral Fibers; Phosphorylation; Phytic Acid; Receptor, ErbB-2 | 2005 |
Evaluation of zoledronate, cytochalasin-D, and desferrioxamine on osseointegration in an intra-medullary femoral implant model.
Topics: Animals; Bone Density Conservation Agents; Bone-Anchored Prosthesis; Cytochalasin D; Deferoxamine; Drug Evaluation, Preclinical; Female; Femur; Models, Animal; Nucleic Acid Synthesis Inhibitors; Random Allocation; Rats; Rats, Sprague-Dawley; Siderophores; Zoledronic Acid | 2020 |